A Study of 3mg Once Every Two Weeks Administration of Efsubaglutide Alfa Injection in Type 2 Diabetes Patients.
Clinical trial NCT06849843 · COMPLETED
Trial details
- NCT number
- NCT06849843
- Sponsor
- Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-12-18
- Primary completion
- 2025-05-29
- Enrollment
- 59
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.